• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MXCT

    MaxCyte Inc.

    Subscribe to $MXCT
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: maxcyte.com

    Recent Analyst Ratings for MaxCyte Inc.

    DatePrice TargetRatingAnalyst
    11/29/2023$7.00Buy
    Craig Hallum
    10/15/2021Outperform
    Cowen
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021Outperform
    William Blair
    8/24/2021$19.00Overweight
    Stephens
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$18.00Buy
    Stifel
    8/24/2021$22.00Buy
    BTIG
    See more ratings

    MaxCyte Inc. SEC Filings

    See more
    • MaxCyte Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - MAXCYTE, INC. (0001287098) (Filer)

      6/18/25 4:58:53 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by MaxCyte Inc.

      DEFA14A - MAXCYTE, INC. (0001287098) (Filer)

      5/29/25 4:30:10 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by MaxCyte Inc.

      10-Q - MAXCYTE, INC. (0001287098) (Filer)

      5/8/25 5:04:27 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MAXCYTE, INC. (0001287098) (Filer)

      5/7/25 4:14:32 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEF 14A filed by MaxCyte Inc.

      DEF 14A - MAXCYTE, INC. (0001287098) (Filer)

      4/28/25 4:58:55 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form PRE 14A filed by MaxCyte Inc.

      PRE 14A - MAXCYTE, INC. (0001287098) (Filer)

      4/15/25 4:48:39 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-K filed by MaxCyte Inc.

      10-K - MAXCYTE, INC. (0001287098) (Filer)

      3/11/25 5:05:30 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MAXCYTE, INC. (0001287098) (Filer)

      3/11/25 4:15:14 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MAXCYTE, INC. (0001287098) (Filer)

      1/30/25 7:30:11 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MAXCYTE, INC. (0001287098) (Filer)

      1/13/25 7:30:24 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    MaxCyte Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Masoud Maher bought $489,066 worth of shares (100,000 units at $4.89) (SEC Form 4)

      4 - MAXCYTE, INC. (0001287098) (Issuer)

      6/10/24 5:55:54 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care